Dr. Travis Mickle, PhD, President and CEO of KemPharm, Inc., discusses the FDA approval of their new ADHD drug AZSTARYS(tm) (serdexmethylphenidate and dexmethylphenidate capsule) for ages 6 to adult, a once-a-day pill with rapid onset of 30 mins and lasts 13 hrs without the side effects associated with the current standard of care.
Dr. Mickle founded KemPharm Inc. after the discovery of LAT(r), a prodrug therapy that uses the Ligand Activated Technology. As Chairman of the Board, President, Chief Executive Officer and CEO of KemPharm Inc., he is responsible for the company’s scientific strategy and business. He also assists in the development of KemPharm’s proprietary prodrugs pipeline. Before founding KemPharm Dr. Mickle was Director of Drug Discovery at New River Pharmaceuticals, where he was also the chief inventor of Vyvanse(r), an amphetamine-based prodrug for attention deficit hyperactivity disorder (ADHD). Vyvanse has become the market leader in the ADHD market, which is estimated to be worth $17 trillion. Vyvanse’s success and the robust prodrugs that Dr. Mickle created for ADHD, pain, and thyroid dysfunctions led to New River Pharmaceuticals being purchased by Shire Pharmaceuticals PLC for $2.6 Billion. Over his career, Dr. Mickle was granted more 80 US patents than EP (European Patents) and has authored more 100 patent application US and worldwide. His focus is on abuse-deterrent drugs in pain management, mental health, and multiple patents for hydrocodone and methylphenidate. Dr. Mickle is also the principal investigator or secondary investigator for numerous scientific articles and abstracts. Dr. Mickle earned his Ph.D. from the University of Iowa as well as his B.A. Simpson College.
Visit our website
Follow us on social media
Subscribe to our podcast channels
– Support usR